Novartis, zeroing in on innovative meds, launches strategic review of India outfit

A Novartis subsidiary in India has become the target of a strategic review as the Swiss pharma focuses its efforts on newer medicines.

As part of a strategic review unveiled Friday, Novartis said it’s evaluating its 70.68% position in Novartis India Limited, a local unit listed on BSE.